Eurofins Scientific, LabCorp Drug Development and Charles River are Dominating the Global Medicinal Chemistry for Drug Discovery Market 2022

Global Medicinal Chemistry for Drug Discovery Market is expected to grow with the CAGR of 13.5% in the forecast period of 2022 to 2029. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-medicinal-chemistry-for-drug-discovery-market

Global medicinal chemistry for drug discovery market is a highly consolidated market, which includes specific number of key players as well as local players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in global medicinal chemistry for drug discovery market are introducing strong range of services portfolio. This helped companies to maximize the sales with enhanced services portfolio.

For instance,

  • In October, Lonza unveiled its latest PyroCell MAT System to detect various pyrogens sensitively and sustainably, without the need for laboratory animals. The product was launched with a full solution with optimized MAT reagents from Sanquin and media and accessories from Lonza. The company's introduction of this new product has boosted its credibility and market demand.

Eurofins Scientific, is dominating player in global medicinal chemistry for drug discovery market. The other key players existing in the market includes LabCorp Drug development, Charles River, Wuxi Apptec, Evotec SE, Priamal Pharma Solutions, Thermo Fisher Scientific Inc., Aurigene Pharmaceuticals Services, Aurelia Bioscience, BioBlocks Inc., Certara Inc., Drug Discovery Alliances, Genscript Biotech, Jubilant Biosys, Nanosyn, Nereid Therapeutics, Pfizer Inc., Selvita, Spectris PLC, Sygnature Discovery and Taros Chemical GMBH among others.

Medicinal Chemistry for Drug Discovery MarketEUROFINS SCIENTIFIC

Eurofins Scientific is headquartered in Luxembourg, Germany and was founded in 1987. The company focuses on contributing quality laboratory research and advisory services. Some of the product category include Agro Testing, Bio Pharma Services , Cosmetics & Personal Care, Food and Feed Testing, Forensic Services, Genomic Services, Maritime Services, Environment Testing, Biopharma Services, Medicinal Chemistry, Reach Services out of which Medicinal Chemistry is the market focused category.

  • In February, Eurofins Scientific acquired Beacon Discovery for its innovative approach, years of experience in drug discovery and development, and profound expertise in GPCR (G-Protein Coupled Receptor) research. This will help the company to increase its global presence

The company has presence in Europe, North America, Asia-Pacific, South America, Middle East and Africa. In addition to it, the company also generates its revenue from the various subsidiary companies such as Eurofins Agroscience Services Pty Ltd., Eurofins Agroscience Testing Pty Ltd., Eurofins Agroscience Services Ltda., Eurofins Belgium NV, Eurofins Environment Testing Canada, Inc., among others.                 

LABCORP DRUG DEVELOPMENT

Labcorp Drug Development is headquartered in Burlington, North Caroline, USA and was founded in year 1995. The company focuses on harnessing science for human good. And work day and night, around the world, to deliver answers for all the health questions. Some of the product category include Clinical  Laboratory  Business, End-to-end  Drug  Development,  Medical  Device  and  Companion  Diagnostic  Development  Solutions  from  Early Stage  Research  to  Clinical  Development  and  Commercial  Market  Access out of which End-to-end  Drug  Development, Development  Solutions  from  Early Stage  Research  to  Clinical  Development is the market focused category.

  • In December, LABCORP completed the acquisition of Toxikon Corporation. The addition of Toxikon to Labcorp Drug development boost Labcorp's strong expanding nonclinical development testing capabilities for pharmaceutical, biotech clients and creates a strategic footprint in drug development.

The company has wide global presence across the world as North America, Europe, Latin America, Africa, Asia Pacific with its various subsidiaries such as Litholink (Chicago), Esoterix Genetic Laboratories LLC (USA), MedTox (USA), Pathology Associates Medical Laboratories (PAML) (USA) among others.

CHARLES RIVER

Charles River is headquartered in Massachusetts, U.S. and was founded in year 1947. The company focuses on excellent science and on improving the quality of people’s lives, with strong sense of purpose for the betterment of the society. Some of the product category include Research Models & Services, Discovery Services, Safety Assessment, Laboratory Sciences, Cell & Gene Therapy CDMO Solutions, Biologics Testing Solutions, Avian Vaccine Services, QC Microbial Solutions, Scientific & Regulatory Advisory Services, Scientific Staffing, Training, & Operations Support out of which Drug Discovery is the market focused category.

  • In October, Charles River Laboratories International and ATEM Structural Discovery (ATEM) announced the formation of a strategic partnership to provide clients access to ATEM’s cryo-electron microscopy (cryo-EM) service solutions. Cryo-EM is a technique that determines the 3D structures of proteins and is utilized to identify how proteins function, how they malfunction in disease, and the most effective way to target them with therapies. This will enhance the service portfolio of the company.
  • In May, Charles River Laboratories International announced that it had signed a definitive agreement to acquire Vigene Biosciences, Inc., a premier, U.S.-based gene therapy contract development and manufacturing organization (CDMO) providing viral vector-based gene delivery solutions. This will enhance the company’s global presence.

The company has wide global presence across the Americas, Europe, Asia-Pacific. In addition to it, the company also generates its revenue from the various subsidiary companies such as HemaCare and Cellero are wholly-owned subsidiaries.